Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06698965 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the incidence of myelosuppression and anti-tumor effects in patients.
Trial Details
NCT Number NCT06698965
Lead Sponsor Shanghai Chest Hospital
Collaborators: Jiangsu Simcere Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Lung Cancer, Small Cell
Related terms Small Cell Lung Carcinoma
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov